Research programme: glaucoma therapeutics - Colby PharmaceuticalsAlternative Names: OT-411; OT-440
Latest Information Update: 13 Dec 2012
At a glance
- Originator Othera Pharmaceuticals
- Developer Colby Pharmaceuticals
- Class Hydroxylamines
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Glaucoma